MTOR and tuberous sclerosis: Studying mTOR inhibitors as pharmacotherapeutic intervention in neurodegenerative pathologies with ASD features (tuberous sclerosis) showed that sirolimus was safe and effective in 2-year-old children and even better tolerated in kids than adults at full-schedule dosing in other neurodegenerative pathologies linked to mTOR activation [85].